GoodRx Now Offers Novo Nordisk’s Cash Price for the Launch of the Wegovy® Pill
GoodRx Holdings, Inc. - Class A (GDRX)
Company Research
Source: Business Wire
Consumers can soon go to GoodRx for Weight Loss to determine eligibility and obtain a prescription for the first and only oral GLP-1 formulation SANTA MONICA, Calif.--(BUSINESS WIRE)--GoodRx (Nasdaq: GDRX), the leading platform for medication savings in the U.S., today announced that the newly FDA-approved Wegovy® pill (oral semaglutide) is now available at a cash price of $149 per month at more than 70,000 pharmacies nationwide via GoodRx. For consumers looking to easily evaluate their options for both treatment and access to the medication, they will soon be able to connect with a licensed healthcare provider through GoodRx for Weight Loss to determine eligibility and obtain a prescription when appropriate. The arrival of the Wegovy pill on GoodRx represents a significant step forward in making GLP-1 treatments more affordable and accessible for people looking to begin or advance their weight-loss journey.“We’re excited to help consumers access one of the most anticipated weight-
Show less
Read more
Impact Snapshot
Event Time:
GDRX
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
|
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
|---|---|---|
|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
| Last Price | ||
| VWAP | ||
|
High:
|
Max Up |
High:
|
|
Low:
|
Max Down |
Low:
|
|
%
|
Post news range |
%
|
|
|
Price change |
|
|
|
Price Change Percentage |
|
|
|
S&P 500 (SPX) |
|
|
%
|
Volume ratio |
%
|
| Volume | ||
| Ticks | ||
|
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
GDRX alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
GDRX alerts
High impacting GoodRx Holdings, Inc. - Class A news events
Weekly update
A roundup of the hottest topics
GDRX
News
- Surescripts and GoodRx Partner to Advance Patient Price TransparencyBusiness Wire
- BofA Maintains Underperform Rating on GoodRx (GDRX) While Trimming PT to $2.60 [Yahoo! Finance]Yahoo! Finance
- GoodRx (NASDAQ:GDRX) had its price target lowered by analysts at Citigroup Inc. from $5.00 to $4.50. They now have a "buy" rating on the stock.MarketBeat
- GoodRx Launches RxSmartSaver at Giant Eagle Pharmacies [Yahoo! Finance]Yahoo! Finance
- GoodRx Launches RxSmartSaver at Giant Eagle PharmaciesBusiness Wire
GDRX
Earnings
- 11/4/25 - Beat
GDRX
Sec Filings
- 1/5/26 - Form 4
- 1/5/26 - Form 4
- 12/22/25 - Form 4
- GDRX's page on the SEC website